Cargrilintide 10mg

🔬 What Is Cagrilintide?

• Cagrilintide (also called AM833) is a long-acting amylin analogue developed by Novo Nordisk.

• Amylin is a natural hormone co-secreted with insulin from pancreatic β-cells.

• It regulates satiety, gastric emptying, and glucagon secretion.

• Cagrilintide is modified to have a much longer half-life than natural amylin, allowing once-weekly injection.

⚙️ Mechanism of Action

• Binds to amylin and calcitonin receptors in the brain.

• Effects:

  • Reduces appetite & cravings

  • Slows gastric emptying → prolonged satiety

  • Suppresses glucagon → better post-meal glucose control

  • Supports weight loss when combined with GLP-1 agonists

📊 Clinical Findings

• In trials, Cagrilintide alone led to significant weight loss compared to placebo.

• The most powerful effect was seen when combined with semaglutide (GLP-1 RA):

  • In Phase 2 trials, cagrilintide + semaglutide 2.4 mg resulted in 15–17% average body weight loss after 20 weeks—greater than semaglutide alone.

• Also showed improvements in:

  • Glycemic control (in T2D patients)

  • Cardiometabolic markers (blood pressure, cholesterol, liver fat)

⚠️ Side Effects

• Most common: GI issues (nausea, vomiting, constipation), especially during dose escalation.

• Other: decreased appetite (intended effect), injection site reactions.

• Tends to be well tolerated with slow titration.

✅ Key Takeaways

• Cagrilintide = long-acting amylin analogue, being studied for obesity and T2D.

• Works by reducing appetite, slowing gastric emptying, and improving glucose control.

• Once-weekly injection, often tested in combo with semaglutide for enhanced weight loss.

• Results: Combination therapy shows greater weight reduction than semaglutide alone.

• Status: In Phase 3 trials as of 2025; not yet FDA-approved.